Signed point-of-view analysis from named Meticulous specialists — what the data means for your market, and what they would do about it. Every perspective links to the verified report behind it.
As screening guidelines catch smaller and more ambiguous findings, biopsy volume grows even before treatment volume does. This market is an early indicator of broader breast cancer detection trends
Newer device-based BPH treatments aren't necessarily more effective than surgery, but they get patients home the same day. That trade-off is what's shifting volume in this category
This is about as demographically predictable as medtech gets. Growth tracks osteoporosis-related fracture incidence closely, with limited disruption from new treatment paradigms
As therapeutic endoscopy expands into resections that once required open surgery, reliable closure technology is the enabling piece. Growth here is really a proxy for that broader shift
Rising dry eye prevalence, closely tied to screen exposure, is a demand driver that shows no sign of reversing. Device-based treatment is gaining share from drops precisely because it's a one-time procedure, not a daily habit
Traditional cuff-based monitoring has a compliance problem: people stop measuring. AI-driven cuffless approaches make monitoring passive, which is why this segment is outrunning the broader wearables category
Capsule endoscopy's growth tracks patient preference as much as diagnostic accuracy. Given a choice, most patients and referring physicians are choosing the option that doesn't require sedation
As more gene therapies reach approval, the vector and delivery platforms behind them become the recurring, picks-and-shovels part of the market. That's where durable growth tends to sit
Each coverage area is led by named specialists who publish continuously against a live syndicated report library.
An analyst perspective is a signed point-of-view article in which a named Meticulous Research specialist interprets market data and states what they would do about it. Each perspective is backed by a verified syndicated report and carries the analyst's name, coverage area and publication date.
Every statistic cited in a perspective traces through the Meticulous Standard's five-link evidence chain back to a primary source. Each perspective also links to the syndicated report containing the underlying model, segmentation, and methodology, so a reader can audit the claim rather than take it on trust.
Yes — all analyst perspectives are published free of charge. The underlying reports, which contain the full data models, segmentation, and forecasts, are sold separately or available through a DataOne subscription.
Food & nutrition, energy & power, ICT & artificial intelligence, healthcare & life sciences, semiconductors & electronics, and mobility & transportation — 30+ industries in total across the syndicated library.
Yes. Every perspective is signed, and clients can request an analyst briefing to discuss the view against their own decision. Contact sales@meticulousresearch.com or call +1 646-781-8004.
Tell us the decision you're facing and we'll put the right specialist on it — through a briefing or a scoped custom study.
Search across reports, blogs, press releases, and industries